Free Trial

Charles River Laboratories International (CRL) Financials

Charles River Laboratories International logo
$136.31 -2.34 (-1.69%)
Closing price 05/28/2025 03:59 PM Eastern
Extended Trading
$137.75 +1.44 (+1.06%)
As of 07:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Annual Income Statements for Charles River Laboratories International

Annual Income Statements for Charles River Laboratories International

This table shows Charles River Laboratories International's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/28/2024 12/30/2023 12/31/2022 12/25/2021 12/26/2020 12/28/2019 12/29/2018 12/30/2017 12/31/2016 12/26/2015
Net Income / (Loss) Attributable to Common Shareholders
22 475 486 391 364 252 226 123 155 149
Consolidated Net Income / (Loss)
25 480 493 399 365 254 229 125 156 151
Net Income / (Loss) Continuing Operations
25 480 493 399 365 254 227 126 156 152
Total Pre-Tax Income
93 581 623 481 447 304 282 297 223 195
Total Operating Income
227 617 651 590 433 351 331 288 238 206
Total Gross Profit
1,332 1,503 1,463 1,335 1,074 958 840 701 644 531
Total Revenue
4,050 4,129 3,976 3,540 2,924 2,621 2,266 1,858 1,681 1,363
Operating Revenue
4,050 4,129 3,976 3,540 2,924 2,621 2,266 1,858 1,681 1,363
Total Cost of Revenue
2,718 2,627 2,513 2,206 1,850 1,663 1,426 1,157 1,037 832
Operating Cost of Revenue
2,718 2,627 2,513 2,206 1,850 1,663 1,426 1,157 1,037 832
Total Operating Expenses
1,104 885 812 745 641 607 509 413 406 325
Selling, General & Admin Expense
751 748 665 620 529 518 444 371 365 300
Amortization Expense
138 137 147 125 112 90 65 41 42 24
Impairment Charge
215 0.00 0.00 - - - - - - -
Total Other Income / (Expense), net
-134 -36 -28 -109 14 -47 -50 8.67 -15 -11
Interest Expense
126 137 59 74 86 61 64 30 28 15
Interest & Investment Income
8.58 5.20 0.78 0.65 0.83 1.52 0.81 0.69 1.31 1.04
Other Income / (Expense), net
-17 96 31 -36 100 12 13 38 12 3.01
Income Tax Expense
68 101 130 82 82 50 54 171 67 43
Preferred Stock Dividends Declared
12 0.00 0.00 - - - - - - -
Net Income / (Loss) Attributable to Noncontrolling Interest
3.09 5.75 6.38 7.86 1.00 2.04 2.35 2.09 1.60 1.77
Basic Earnings per Share
$0.20 $9.27 $9.57 $7.77 $7.35 $5.17 $4.72 $2.60 $3.29 $3.21
Weighted Average Basic Shares Outstanding
51.38M 51.23M 50.81M 50.29M 49.55M 48.73M 47.95M 47.48M 47.01M 46.50M
Diluted Earnings per Share
$0.20 $9.22 $9.48 $7.60 $7.20 $5.07 $4.62 $2.54 $3.23 $3.13
Weighted Average Diluted Shares Outstanding
51.63M 51.45M 51.30M 51.43M 50.61M 49.69M 49.02M 48.56M 47.96M 46.50M
Weighted Average Basic & Diluted Shares Outstanding
51.14M 51.35M 50.99M 50.49M 49.78M 48.96M 48M 47.40M 47.01M 46.50M

Quarterly Income Statements for Charles River Laboratories International

This table shows Charles River Laboratories International's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/29/2025 12/28/2024 9/28/2024 6/29/2024 3/30/2024 12/30/2023 9/30/2023 7/1/2023 4/1/2023 12/31/2022 9/24/2022
Net Income / (Loss) Attributable to Common Shareholders
25 -214 70 94 73 187 87 97 103 187 96
Consolidated Net Income / (Loss)
26 -214 70 94 74 189 88 99 104 189 98
Net Income / (Loss) Continuing Operations
26 -214 70 94 74 189 88 99 104 189 98
Total Pre-Tax Income
36 -217 91 120 99 209 113 129 131 245 123
Total Operating Income
75 -168 117 152 126 133 152 165 168 164 151
Total Gross Profit
318 284 349 354 345 364 362 399 378 399 370
Total Revenue
984 1,003 1,010 1,026 1,012 1,013 1,027 1,060 1,029 1,100 989
Operating Revenue
984 1,003 1,010 1,026 1,012 1,013 1,027 1,060 1,029 1,100 989
Total Cost of Revenue
666 718 661 672 667 649 665 661 652 701 619
Operating Cost of Revenue
666 718 661 672 667 649 665 661 652 701 619
Total Operating Expenses
243 452 232 202 219 231 210 234 210 235 219
Selling, General & Admin Expense
178 196 199 170 186 197 176 200 175 200 184
Amortization Expense
65 41 32 32 33 34 34 34 35 35 36
Total Other Income / (Expense), net
-39 -49 -26 -32 -27 76 -39 -36 -37 81 -28
Interest Expense
28 28 30 33 35 34 34 35 34 35 11
Interest & Investment Income
1.40 1.84 1.53 3.01 2.20 1.59 1.37 1.43 0.81 0.34 0.12
Other Income / (Expense), net
-12 -23 2.59 -2.24 5.83 108 -6.26 -2.66 -3.28 116 -17
Income Tax Expense
10 -3.04 21 25 25 20 25 29 27 56 25
Preferred Stock Dividends Declared
0.00 - 0.60 - - - 0.00 - - - -
Net Income / (Loss) Attributable to Noncontrolling Interest
0.41 -8.27 0.64 3.97 6.75 1.87 0.63 2.42 0.82 1.70 1.14
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)
0.00 - 0.38 0.30 0.40 - 0.00 0.00 0.00 - -
Basic Earnings per Share
$0.50 ($4.20) $1.34 $1.75 $1.31 $3.66 $1.70 $1.89 $2.02 $3.68 $1.90
Weighted Average Basic Shares Outstanding
50.68M 51.38M 51.39M 51.55M 51.44M 51.23M 51.28M 51.22M 51.10M 50.81M 50.87M
Diluted Earnings per Share
$0.50 ($4.17) $1.33 $1.74 $1.30 $3.63 $1.69 $1.89 $2.01 $3.66 $1.88
Weighted Average Diluted Shares Outstanding
50.85M 51.63M 51.58M 51.85M 51.84M 51.45M 51.61M 51.47M 51.43M 51.30M 51.28M
Weighted Average Basic & Diluted Shares Outstanding
49.12M 51.14M 51.14M 51.63M 51.51M 51.35M 51.30M 51.27M 51.18M 50.99M 50.88M

Annual Cash Flow Statements for Charles River Laboratories International

This table details how cash moves in and out of Charles River Laboratories International's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/28/2024 12/30/2023 12/31/2022 12/25/2021 12/26/2020 12/28/2019 12/29/2018 12/30/2017 12/31/2016 12/26/2015
Net Change in Cash & Equivalents
-79 43 -5.10 13 -6.93 43 40 35 2.93 -30
Net Cash From Operating Activities
735 684 620 761 547 481 441 318 317 307
Net Cash From Continuing Operating Activities
735 684 620 761 547 481 441 318 317 307
Net Income / (Loss) Continuing Operations
25 480 493 399 365 254 227 126 156 152
Consolidated Net Income / (Loss)
25 480 493 399 365 254 229 125 156 151
Depreciation Expense
362 314 304 266 235 198 162 131 127 95
Non-Cash Adjustments To Reconcile Net Income
452 27 42 129 -18 34 75 19 60 29
Changes in Operating Assets and Liabilities, net
-104 -138 -219 -32 -36 -4.82 -23 43 -26 31
Net Cash From Investing Activities
-245 -563 -608 -1,438 -602 -682 -955 -73 -693 -328
Net Cash From Continuing Investing Activities
-245 -563 -608 -1,438 -602 -682 -955 -73 -693 -328
Purchase of Property, Plant & Equipment
-233 -319 -325 -229 -167 -141 -140 -82 -55 -63
Acquisitions
-5.48 -195 -283 -1,293 -419 -516 -825 -25 -648 -248
Purchase of Investments
-53 -54 -158 -46 -27 -22 -25 -46 -40 -34
Divestitures
0.00 0.00 163 123 0.00 0.00 - 72 0.00 0.00
Sale and/or Maturity of Investments
42 6.67 4.55 6.53 11 0.94 36 9.13 48 20
Other Investing Activities, net
4.55 -2.29 -9.35 0.26 -1.07 -3.89 -0.81 -0.52 3.69 -2.22
Net Cash From Financing Activities
-551 -86 -42 673 47 232 558 -208 381 -7.26
Net Cash From Continuing Financing Activities
-551 -86 -42 673 47 232 558 -208 381 -7.26
Repayment of Debt
-1,525 -856 -2,940 -6,281 -2,206 -3,143 -2,221 -377 -675 -422
Repurchase of Common Equity
-119 -24 -39 -41 -24 -18 -14 -107 -12 -117
Issuance of Debt
1,082 776 2,952 6,951 2,231 3,358 2,755 237 1,045 493
Other Financing Activities, net
12 18 -16 43 47 35 38 39 23 39
Effect of Exchange Rate Changes
-17 8.04 26 18 0.79 11 - - - -

Quarterly Cash Flow Statements for Charles River Laboratories International

This table details how cash moves in and out of Charles River Laboratories International's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/29/2025 12/28/2024 9/28/2024 6/29/2024 3/30/2024 12/30/2023 9/30/2023 7/1/2023 4/1/2023 12/31/2022 9/24/2022
Net Change in Cash & Equivalents
26 -6.07 31 -158 54 119 -43 -0.11 -32 45 -11
Net Cash From Operating Activities
172 159 252 194 130 221 205 148 109 235 133
Net Cash From Continuing Operating Activities
172 159 252 194 130 221 205 148 109 235 133
Net Income / (Loss) Continuing Operations
26 -214 70 94 74 189 88 99 104 189 98
Consolidated Net Income / (Loss)
26 -214 70 94 74 189 88 99 104 189 98
Depreciation Expense
120 102 88 86 85 81 79 78 77 78 75
Non-Cash Adjustments To Reconcile Net Income
52 347 42 38 25 -58 44 8.08 33 -80 38
Changes in Operating Assets and Liabilities, net
-27 -76 52 -25 -55 9.77 -5.37 -37 -105 49 -77
Net Cash From Investing Activities
-45 -76 -21 -62 -86 -238 -80 -77 -169 44 -92
Net Cash From Continuing Investing Activities
-45 -76 -21 -62 -86 -238 -80 -77 -169 44 -92
Purchase of Property, Plant & Equipment
-59 -76 -39 -39 -79 -78 -66 -67 -107 -89 -72
Purchase of Investments
-5.30 -7.61 -9.73 -22 -14 -18 -14 -10 -13 -29 -21
Divestitures
17 - - - - - - - - - -
Sale and/or Maturity of Investments
1.60 2.22 27 4.86 7.50 2.71 1.01 0.99 1.95 1.45 2.90
Other Investing Activities, net
0.10 4.91 0.01 -0.09 -0.28 -0.25 -0.99 -0.10 -0.96 -2.40 -2.17
Net Cash From Financing Activities
-105 -76 -208 -286 18 124 -163 -71 25 -249 -52
Net Cash From Continuing Financing Activities
-105 -76 -208 -286 18 124 -163 -71 25 -249 -52
Repayment of Debt
-149 -181 -343 -706 -295 -321 -218 -160 -157 -410 -657
Repurchase of Common Equity
-353 -0.12 -101 -8.91 -9.35 -0.14 -0.04 -4.97 -19 -0.16 -0.02
Issuance of Debt
416 105 236 440 301 443 51 89 193 154 618
Other Financing Activities, net
-19 0.77 0.78 -11 22 1.16 3.94 3.93 9.08 7.40 -13
Effect of Exchange Rate Changes
5.27 -13 7.70 -3.34 -8.39 13 -6.19 -0.16 1.67 15 -0.03

Annual Balance Sheets for Charles River Laboratories International

This table presents Charles River Laboratories International's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/28/2024 12/30/2023 12/31/2022 12/25/2021 12/26/2020 12/28/2019 12/29/2018 12/30/2017 12/31/2016 12/26/2015
Total Assets
7,528 8,195 7,603 7,024 5,491 4,693 3,856 2,930 2,712 2,068
Total Current Assets
1,403 1,609 1,439 1,274 1,201 1,021 898 827 657 559
Cash & Equivalents
195 277 234 241 228 238 195 164 118 118
Accounts Receivable
721 780 752 643 618 514 472 430 364 270
Inventories, net
279 380 256 199 186 161 128 115 96 94
Prepaid Expenses
209 171 197 191 169 109 102 118 34 30
Plant, Property, & Equipment, net
1,604 1,640 1,466 1,291 0.00 1,044 933 782 756 678
Total Noncurrent Assets
4,521 4,947 4,698 4,459 4,290 2,627 2,025 1,321 1,299 831
Long-Term Investments
218 244 312 201 - - - - - -
Goodwill
2,847 3,095 2,850 2,712 1,809 1,541 1,247 805 788 439
Intangible Assets
723 864 955 1,061 788 689 611 370 394 281
Noncurrent Deferred & Refundable Income Taxes
42 40 41 40 38 45 23 23 29 40
Other Noncurrent Operating Assets
691 703 540 444 1,477 213 144 124 88 72
Total Liabilities & Shareholders' Equity
7,528 8,195 7,603 7,024 5,491 4,693 3,856 2,930 2,712 2,068
Total Liabilities
4,020 4,536 4,579 4,432 3,347 3,026 2,518 1,866 1,858 1,303
Total Current Liabilities
994 1,055 1,092 1,033 840 710 558 464 430 312
Accounts Payable
140 169 206 198 122 111 66 78 68 37
Accrued Expenses
232 228 220 229 150 139 107 90 84 89
Current Deferred Revenue
248 242 264 220 208 172 145 118 128 81
Current Employee Benefit Liabilities
179 213 197 246 207 159 137 101 93 73
Other Current Liabilities
194 203 205 140 102 91 71 44 27 13
Total Noncurrent Liabilities
3,026 3,481 3,488 3,399 2,507 2,316 1,959 1,402 1,428 991
Long-Term Debt
2,240 2,647 2,708 2,664 1,930 1,850 1,637 1,114 1,208 846
Noncurrent Deferred & Payable Income Tax Liabilities
107 191 216 240 217 167 144 90 56 48
Other Noncurrent Operating Liabilities
679 642 565 496 361 299 179 195 159 89
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest
41 57 42 53 25 29 19 17 15 28
Total Equity & Noncontrolling Interests
3,467 3,602 2,981 2,539 2,118 1,638 1,320 1,047 839 738
Total Preferred & Common Equity
3,462 3,597 2,976 2,535 2,115 1,635 1,317 1,045 837 733
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
3,462 3,597 2,976 2,535 2,115 1,635 1,317 1,045 837 733
Common Stock
1,967 1,906 1,805 1,719 1,628 1,532 1,448 2,561 2,478 2,399
Retained Earnings
1,812 1,887 1,433 981 625 280 42 289 165 11
Treasury Stock
0.00 0.00 0.00 0.00 0.00 0.00 -0.06 -1,660 -1,553 -1,541
Accumulated Other Comprehensive Income / (Loss)
-317 -196 -262 -165 -139 -178 -173 -145 -254 -136
Noncontrolling Interest
5.45 5.39 4.79 4.16 3.57 3.24 2.45 2.33 2.36 4.49

Quarterly Balance Sheets for Charles River Laboratories International

This table presents Charles River Laboratories International's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/29/2025 12/28/2024 9/28/2024 6/29/2024 3/30/2024 12/30/2023 9/30/2023 7/1/2023 4/1/2023 12/31/2022 9/24/2022
Total Assets
7,582 7,528 8,004 7,948 8,153 8,195 7,607 7,772 7,699 7,603 7,383
Total Current Assets
1,506 1,403 1,495 1,499 1,668 1,609 1,444 1,505 1,448 1,439 1,415
Cash & Equivalents
229 195 210 179 327 277 157 200 202 234 194
Accounts Receivable
757 721 754 762 787 780 799 801 788 752 771
Inventories, net
290 279 336 349 361 380 293 285 263 256 262
Prepaid Expenses
230 209 194 209 193 171 195 218 196 197 189
Plant, Property, & Equipment, net
1,587 1,604 1,640 1,614 1,619 1,640 1,525 1,530 1,494 1,466 1,381
Total Noncurrent Assets
4,489 4,521 4,869 4,835 4,866 4,947 4,637 4,738 4,757 4,698 4,587
Long-Term Investments
214 218 236 232 244 244 302 300 294 312 -
Goodwill
2,873 2,847 3,125 3,080 3,070 3,095 2,885 2,917 2,902 2,850 2,776
Intangible Assets
656 723 778 800 828 864 886 930 958 955 968
Noncurrent Deferred & Refundable Income Taxes
49 42 38 36 37 40 34 39 41 41 40
Other Noncurrent Operating Assets
697 691 692 687 688 703 530 553 562 540 803
Total Liabilities & Shareholders' Equity
7,582 7,528 8,004 7,948 8,153 8,195 7,607 7,772 7,699 7,603 7,383
Total Liabilities
4,341 4,020 4,176 4,175 4,449 4,536 4,256 4,472 4,543 4,579 4,711
Total Current Liabilities
1,051 994 1,012 948 955 1,055 994 1,008 981 1,092 1,014
Accounts Payable
149 140 136 133 130 169 136 140 120 206 182
Accrued Expenses
242 232 208 192 191 228 198 221 221 220 197
Current Deferred Revenue
250 248 252 247 256 242 250 257 262 264 251
Current Employee Benefit Liabilities
197 179 211 177 190 213 224 191 176 197 200
Other Current Liabilities
211 194 205 198 188 203 185 199 202 205 182
Total Noncurrent Liabilities
3,290 3,026 3,164 3,228 3,494 3,481 3,262 3,465 3,561 3,488 3,697
Long-Term Debt
2,511 2,240 2,327 2,409 2,660 2,647 2,514 2,678 2,744 2,708 2,937
Noncurrent Deferred & Payable Income Tax Liabilities
107 107 168 165 180 191 185 207 212 216 196
Other Noncurrent Operating Liabilities
672 679 670 653 653 642 563 579 605 565 564
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest
42 41 41 46 58 57 40 42 43 42 39
Total Equity & Noncontrolling Interests
3,200 3,467 3,787 3,727 3,646 3,602 3,311 3,258 3,114 2,981 2,633
Total Preferred & Common Equity
3,194 3,462 3,782 3,723 3,640 3,597 3,306 3,252 3,109 2,976 2,627
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
3,194 3,462 3,782 3,723 3,640 3,597 3,306 3,252 3,109 2,976 2,627
Common Stock
1,979 1,967 1,972 1,957 1,940 1,906 1,878 1,851 1,831 1,805 1,781
Retained Earnings
1,838 1,812 2,123 2,054 1,960 1,887 1,720 1,633 1,536 1,433 1,280
Treasury Stock
-357 0.00 -120 -18 -9.35 0.00 -24 -24 -19 0.00 -38
Accumulated Other Comprehensive Income / (Loss)
-265 -317 -193 -270 -250 -196 -268 -208 -239 -262 -396
Noncontrolling Interest
5.78 5.45 4.85 4.29 5.72 5.39 4.77 5.85 5.29 4.79 5.89

Annual Metrics And Ratios for Charles River Laboratories International

This table displays calculated financial ratios and metrics derived from Charles River Laboratories International's official financial filings.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/28/2024 12/30/2023 12/31/2022 12/25/2021 12/26/2020 12/28/2019 12/29/2018 12/30/2017 12/31/2016 12/26/2015
Growth Metrics
- - - - - - - - - -
Revenue Growth
-1.92% 3.86% 12.31% 21.08% 11.55% 15.67% 21.99% 10.48% 23.34% 5.06%
EBITDA Growth
-44.24% 4.22% 20.24% 6.76% 36.70% 10.88% 10.77% 21.60% 23.54% 6.20%
EBIT Growth
-70.42% 4.59% 23.02% 3.99% 46.57% 5.46% 5.70% 30.77% 19.03% 11.18%
NOPAT Growth
-87.89% -0.90% 5.18% 38.42% 20.51% 9.75% 119.25% -26.70% 3.56% 23.57%
Net Income Growth
-94.74% -2.48% 23.51% 9.18% 43.79% 11.08% 82.32% -19.77% 3.49% 17.85%
EPS Growth
-97.83% -2.74% 24.74% 5.56% 42.01% 9.74% 81.89% -21.36% 3.19% 17.67%
Operating Cash Flow Growth
7.41% 10.37% -18.55% 39.19% 13.65% 9.02% 38.69% 0.37% 3.28% 21.70%
Free Cash Flow Firm Growth
669.25% -163.25% 133.18% -90.64% -5.83% 56.87% -1,096.99% 116.93% -802.84% -116.52%
Invested Capital Growth
-7.78% 11.57% 7.74% 23.57% 17.44% 17.99% 37.04% 3.67% 30.14% 14.53%
Revenue Q/Q Growth
-0.27% -2.05% 5.15% 3.33% 3.54% 3.54% 5.74% 0.63% 7.20% 1.81%
EBITDA Q/Q Growth
-41.70% -3.36% 13.18% -2.88% 12.50% 9.31% 4.80% 0.79% 7.86% 2.72%
EBIT Q/Q Growth
-67.15% -5.15% 18.11% -5.24% 16.71% 11.53% 4.58% 1.77% 7.50% 5.50%
NOPAT Q/Q Growth
-85.83% 1.14% -4.70% 8.82% 8.03% -0.43% 83.08% -39.64% 9.48% 3.81%
Net Income Q/Q Growth
-94.09% -0.03% 11.12% -1.08% 21.11% 8.69% 64.01% -37.19% 8.97% 3.20%
EPS Q/Q Growth
-97.50% -0.32% 11.66% -1.81% 19.80% 8.57% 66.79% -38.05% 9.12% 2.96%
Operating Cash Flow Q/Q Growth
-7.73% -1.98% 0.90% 13.57% -7.18% 9.25% 3.70% 1.79% -0.72% 7.38%
Free Cash Flow Firm Q/Q Growth
283.81% -117.44% -47.29% 57.08% -306.75% -5.17% 13.23% -66.00% 21.87% -267.52%
Invested Capital Q/Q Growth
-6.53% 7.02% -4.28% -6.49% 5.31% 0.01% -0.31% -2.61% -3.45% -0.23%
Profitability Metrics
- - - - - - - - - -
Gross Margin
32.88% 36.39% 36.79% 37.70% 36.72% 36.56% 37.07% 37.73% 38.30% 38.96%
EBITDA Margin
14.14% 24.87% 24.78% 23.15% 26.25% 21.42% 22.35% 24.61% 22.36% 22.32%
Operating Margin
5.61% 14.95% 16.37% 16.66% 14.80% 13.40% 14.62% 15.52% 14.13% 15.14%
EBIT Margin
5.21% 17.26% 17.14% 15.65% 18.22% 13.87% 15.21% 17.55% 14.83% 15.36%
Profit (Net Income) Margin
0.62% 11.63% 12.39% 11.27% 12.49% 9.69% 10.09% 6.75% 9.30% 11.08%
Tax Burden Percent
27.16% 82.64% 79.07% 82.97% 81.70% 83.55% 81.20% 42.25% 70.14% 77.31%
Interest Burden Percent
44.17% 81.55% 91.41% 86.78% 83.93% 83.67% 81.73% 91.08% 89.41% 93.30%
Effective Tax Rate
72.84% 17.36% 20.93% 17.03% 18.30% 16.45% 19.34% 57.71% 29.98% 22.20%
Return on Invested Capital (ROIC)
1.11% 9.30% 10.30% 11.24% 9.81% 9.58% 11.00% 6.05% 9.51% 11.28%
ROIC Less NNEP Spread (ROIC-NNEP)
-0.73% 7.91% 9.29% 6.68% 10.50% 7.06% 7.86% 6.39% 8.45% 9.90%
Return on Net Nonoperating Assets (RNNOA)
-0.40% 5.08% 7.25% 5.60% 9.37% 7.33% 8.05% 7.03% 9.80% 9.28%
Return on Equity (ROE)
0.71% 14.38% 17.54% 16.84% 19.18% 16.91% 19.04% 13.08% 19.31% 20.56%
Cash Return on Invested Capital (CROIC)
9.21% -1.64% 2.84% -9.84% -6.23% -6.93% -20.26% 2.45% -16.68% -2.27%
Operating Return on Assets (OROA)
2.68% 9.02% 9.32% 8.85% 10.46% 8.50% 10.16% 11.56% 10.43% 10.63%
Return on Assets (ROA)
0.32% 6.08% 6.74% 6.37% 7.17% 5.94% 6.74% 4.45% 6.54% 7.67%
Return on Common Equity (ROCE)
0.70% 14.14% 17.22% 16.54% 18.87% 16.61% 18.73% 12.84% 18.72% 19.65%
Return on Equity Simple (ROE_SIMPLE)
0.73% 13.36% 16.55% 15.73% 17.28% 15.54% 17.36% 12.00% 18.69% 20.61%
Net Operating Profit after Tax (NOPAT)
62 510 515 489 354 293 267 122 166 161
NOPAT Margin
1.52% 12.35% 12.95% 13.82% 12.09% 11.19% 11.80% 6.56% 9.89% 11.78%
Net Nonoperating Expense Percent (NNEP)
1.84% 1.39% 1.01% 4.56% -0.69% 2.52% 3.14% -0.33% 1.06% 1.38%
Return On Investment Capital (ROIC_SIMPLE)
1.08% 8.16% 9.05% - - - - - - -
Cost of Revenue to Revenue
67.12% 63.61% 63.21% 62.30% 63.28% 63.44% 62.93% 62.27% 61.70% 61.04%
SG&A Expenses to Revenue
18.54% 18.11% 16.73% 17.51% 18.09% 19.75% 19.59% 19.99% 21.69% 22.04%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
27.27% 21.44% 20.41% 21.04% 21.92% 23.16% 22.45% 22.21% 24.17% 23.81%
Earnings before Interest and Taxes (EBIT)
211 713 681 554 533 363 345 326 249 209
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
573 1,027 985 820 768 562 506 457 376 304
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
2.75 3.37 3.72 7.35 5.92 4.54 4.08 4.96 4.31 5.09
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 277.92
Price to Revenue (P/Rev)
2.35 2.94 2.79 5.26 4.28 2.83 2.37 2.79 2.14 2.74
Price to Earnings (P/E)
428.75 25.55 22.80 47.65 34.37 29.44 23.74 42.02 23.30 25.01
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.23% 3.91% 4.39% 2.10% 2.91% 3.40% 4.21% 2.38% 4.29% 4.00%
Enterprise Value to Invested Capital (EV/IC)
2.14 2.47 2.56 4.34 3.67 2.74 2.44 3.02 2.40 2.97
Enterprise Value to Revenue (EV/Rev)
2.81 3.47 3.34 5.91 4.89 3.47 3.03 3.33 2.82 3.31
Enterprise Value to EBITDA (EV/EBITDA)
19.90 13.94 13.49 25.51 18.63 16.21 13.56 13.53 12.61 14.82
Enterprise Value to EBIT (EV/EBIT)
54.04 20.08 19.51 37.75 26.85 25.04 19.92 18.97 19.01 21.54
Enterprise Value to NOPAT (EV/NOPAT)
184.51 28.06 25.83 42.73 40.45 31.02 25.69 50.72 28.50 28.09
Enterprise Value to Operating Cash Flow (EV/OCF)
15.51 20.93 21.46 27.48 26.17 18.93 15.57 19.44 14.96 14.70
Enterprise Value to Free Cash Flow (EV/FCFF)
22.25 0.00 93.50 0.00 0.00 0.00 0.00 125.19 0.00 0.00
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
0.64 0.72 0.90 1.03 0.92 1.13 1.25 1.08 1.45 1.13
Long-Term Debt to Equity
0.64 0.72 0.90 1.03 0.90 1.11 1.22 1.05 1.41 1.11
Financial Leverage
0.55 0.64 0.78 0.84 0.89 1.04 1.02 1.10 1.16 0.94
Leverage Ratio
2.19 2.36 2.60 2.64 2.67 2.85 2.82 2.94 2.95 2.68
Compound Leverage Factor
0.97 1.93 2.38 2.29 2.24 2.38 2.31 2.68 2.64 2.50
Debt to Total Capital
38.97% 41.98% 47.24% 50.68% 48.01% 53.12% 55.48% 51.84% 59.13% 52.99%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 1.22% 1.08% 1.05% 1.40% 1.31% 1.05%
Long-Term Debt to Total Capital
38.97% 41.98% 47.24% 50.68% 46.80% 52.03% 54.44% 50.43% 57.82% 51.95%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.81% 0.99% 0.82% 1.09% 0.70% 0.90% 0.70% 0.86% 0.81% 2.00%
Common Equity to Total Capital
60.22% 57.04% 51.93% 48.23% 51.28% 45.98% 43.82% 47.31% 40.06% 45.01%
Debt to EBITDA
3.91 2.58 2.75 3.25 2.58 3.36 3.29 2.50 3.28 2.84
Net Debt to EBITDA
3.19 2.07 2.19 2.71 2.28 2.94 2.91 2.15 2.97 2.45
Long-Term Debt to EBITDA
3.91 2.58 2.75 3.25 2.51 3.29 3.23 2.44 3.21 2.78
Debt to NOPAT
36.28 5.19 5.26 5.44 5.60 6.44 6.24 9.39 7.43 5.37
Net Debt to NOPAT
29.59 4.17 4.20 4.54 4.95 5.62 5.51 8.05 6.72 4.64
Long-Term Debt to NOPAT
36.28 5.19 5.26 5.44 5.46 6.30 6.12 9.14 7.26 5.27
Altman Z-Score
2.45 2.80 2.59 3.52 3.34 2.45 2.28 2.95 2.27 2.86
Noncontrolling Interest Sharing Ratio
1.52% 1.64% 1.86% 1.82% 1.60% 1.76% 1.66% 1.87% 3.06% 4.40%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
1.41 1.52 1.32 1.23 1.43 1.44 1.61 1.78 1.53 1.79
Quick Ratio
0.92 1.00 0.90 0.86 1.01 1.06 1.20 1.28 1.12 1.24
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
512 -90 142 -429 -225 -212 -492 49 -292 -32
Operating Cash Flow to CapEx
315.31% 214.71% 190.82% 332.56% 328.16% 342.27% 314.98% 385.87% 573.18% 485.10%
Free Cash Flow to Firm to Interest Expense
4.05 -0.66 2.40 -5.80 -2.60 -3.49 -7.72 1.66 -10.53 -2.14
Operating Cash Flow to Interest Expense
5.82 5.00 10.45 10.29 6.32 7.90 6.92 10.68 11.44 20.36
Operating Cash Flow Less CapEx to Interest Expense
3.97 2.67 4.97 7.20 4.40 5.59 4.72 7.91 9.44 16.16
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.52 0.52 0.54 0.57 0.57 0.61 0.67 0.66 0.70 0.69
Accounts Receivable Turnover
5.40 5.39 5.70 5.62 5.17 5.32 5.02 4.68 5.30 5.16
Inventory Turnover
8.25 8.26 11.05 11.46 10.68 11.53 11.74 10.97 10.95 9.11
Fixed Asset Turnover
2.50 2.66 2.88 0.00 0.00 2.65 2.64 2.42 2.35 2.01
Accounts Payable Turnover
17.58 14.02 12.44 13.76 15.82 18.71 19.79 15.81 19.73 23.61
Days Sales Outstanding (DSO)
67.65 67.74 64.04 64.99 70.64 68.67 72.66 78.01 68.83 70.69
Days Inventory Outstanding (DIO)
44.23 44.19 33.03 31.84 34.16 31.67 31.08 33.26 33.35 40.08
Days Payable Outstanding (DPO)
20.76 26.04 29.34 26.53 23.08 19.51 18.44 23.09 18.50 15.46
Cash Conversion Cycle (CCC)
91.12 85.89 67.74 70.30 81.72 80.83 85.30 88.18 83.67 95.31
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
5,335 5,786 5,186 4,813 3,895 3,317 2,811 2,051 1,979 1,520
Invested Capital Turnover
0.73 0.75 0.80 0.81 0.81 0.86 0.93 0.92 0.96 0.96
Increase / (Decrease) in Invested Capital
-450 600 373 918 578 506 760 73 458 193
Enterprise Value (EV)
11,393 14,315 13,296 20,910 14,301 9,102 6,867 6,184 4,740 4,511
Market Capitalization
9,520 12,127 11,086 18,631 12,521 7,420 5,373 5,184 3,606 3,734
Book Value per Share
$67.69 $70.12 $58.50 $50.23 $42.51 $33.47 $27.39 $22.07 $17.68 $15.72
Tangible Book Value per Share
($2.12) ($7.06) ($16.29) ($24.54) ($9.69) ($12.19) ($11.24) ($2.74) ($7.29) $0.29
Total Capital
5,748 6,306 5,731 5,256 4,123 3,555 3,006 2,209 2,089 1,629
Total Debt
2,240 2,647 2,708 2,664 1,980 1,888 1,668 1,145 1,235 863
Total Long-Term Debt
2,240 2,647 2,708 2,664 1,930 1,850 1,637 1,114 1,208 846
Net Debt
1,827 2,127 2,162 2,221 1,751 1,650 1,473 981 1,117 745
Capital Expenditures (CapEx)
233 319 325 229 167 141 140 82 55 63
Debt-free, Cash-free Net Working Capital (DFCFNWC)
214 277 114 -0.30 183 112 176 230 137 147
Debt-free Net Working Capital (DFNWC)
409 554 347 241 412 350 371 394 255 265
Net Working Capital (NWC)
409 554 347 241 361 311 340 363 227 247
Net Nonoperating Expense (NNE)
36 30 22 91 -12 39 39 -3.53 9.96 9.52
Net Nonoperating Obligations (NNO)
1,827 2,127 2,162 2,221 1,751 1,650 1,473 987 1,125 755
Total Depreciation and Amortization (D&A)
362 314 304 266 235 198 162 131 127 95
Debt-free, Cash-free Net Working Capital to Revenue
5.29% 6.70% 2.86% -0.01% 6.26% 4.26% 7.75% 12.40% 8.14% 10.75%
Debt-free Net Working Capital to Revenue
10.10% 13.41% 8.74% 6.81% 14.08% 13.34% 16.37% 21.22% 15.14% 19.40%
Net Working Capital to Revenue
10.10% 13.41% 8.74% 6.81% 12.36% 11.87% 14.99% 19.55% 13.51% 18.15%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
$0.20 $9.27 $9.57 $7.77 $7.35 $5.17 $4.72 $2.60 $3.29 $3.21
Adjusted Weighted Average Basic Shares Outstanding
51.38M 51.23M 50.81M 50.29M 49.55M 48.73M 47.95M 47.43M 47.37M 46.72M
Adjusted Diluted Earnings per Share
$0.20 $9.22 $9.48 $7.60 $7.20 $5.07 $4.62 $2.54 $3.23 $3.13
Adjusted Weighted Average Diluted Shares Outstanding
51.63M 51.45M 51.30M 51.43M 50.61M 49.69M 49.02M 47.43M 47.37M 46.72M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $5.17 $4.72 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
51.14M 51.35M 50.99M 50.49M 49.78M 48.96M 48.23M 47.43M 47.37M 46.72M
Normalized Net Operating Profit after Tax (NOPAT)
310 510 515 489 354 293 267 202 166 161
Normalized NOPAT Margin
7.65% 12.35% 12.95% 13.82% 12.09% 11.19% 11.80% 10.86% 9.89% 11.78%
Pre Tax Income Margin
2.30% 14.08% 15.67% 13.58% 15.29% 11.60% 12.43% 15.99% 13.26% 14.33%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
1.67 5.21 11.49 7.50 6.16 5.97 5.40 10.95 9.00 13.90
NOPAT to Interest Expense
0.49 3.73 8.68 6.62 4.09 4.82 4.19 4.09 6.00 10.66
EBIT Less CapEx to Interest Expense
-0.18 2.88 6.02 4.40 4.24 3.66 3.21 8.18 7.00 9.70
NOPAT Less CapEx to Interest Expense
-1.36 1.40 3.20 3.53 2.16 2.51 2.00 1.33 4.01 6.46
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
471.22% 5.03% 7.85% 10.21% 6.56% 7.12% 6.05% 85.22% 7.85% 77.76%

Quarterly Metrics And Ratios for Charles River Laboratories International

This table displays calculated financial ratios and metrics derived from Charles River Laboratories International's official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/29/2025 12/28/2024 9/28/2024 6/29/2024 3/30/2024 12/30/2023 9/30/2023 7/1/2023 4/1/2023 12/31/2022 9/24/2022
Growth Metrics
- - - - - - - - - - -
Revenue Growth
-2.71% -1.08% -1.64% -3.19% -1.73% -7.85% 3.79% 8.92% 12.63% 21.52% 10.40%
EBITDA Growth
-15.82% -127.49% -7.10% -1.86% -10.14% -10.01% 7.25% 7.10% 23.65% 47.41% 0.33%
EBIT Growth
-52.62% -179.11% -17.38% -7.93% -19.93% -13.85% 8.10% 9.93% 37.00% 59.74% -3.75%
NOPAT Growth
-43.33% -197.54% -23.44% -6.29% -28.85% -4.85% -1.31% -11.42% 4.21% -14.34% -9.93%
Net Income Growth
-65.26% -213.12% -20.14% -5.21% -28.35% -0.08% -9.83% -10.14% 9.17% 35.24% -7.18%
EPS Growth
-61.54% -214.88% -21.30% -7.94% -35.32% -0.82% -10.11% -11.27% 11.05% 37.08% -6.47%
Operating Cash Flow Growth
32.19% -27.87% 22.56% 30.66% 18.75% -5.88% 54.73% -0.90% 6.58% 2.40% -24.01%
Free Cash Flow Firm Growth
283.23% 169.39% -263.45% -222.58% -78.76% -94.96% 186.05% 129.17% 83.95% 68.06% 88.55%
Invested Capital Growth
-8.36% -7.78% 5.59% 5.36% 7.19% 11.57% -0.21% -0.27% 5.83% 7.74% 5.25%
Revenue Q/Q Growth
-1.83% -0.71% -1.59% 1.44% -0.19% -1.28% -3.14% 2.97% -6.41% 11.19% 1.65%
EBITDA Q/Q Growth
307.07% -142.41% -11.59% 8.44% -32.38% 43.31% -6.60% -0.72% -32.28% 70.80% -6.73%
EBIT Q/Q Growth
132.80% -258.66% -19.69% 13.35% -45.23% 65.70% -10.50% -1.42% -41.07% 107.92% -8.99%
NOPAT Q/Q Growth
145.75% -229.77% -24.29% 26.07% -21.25% 1.86% -7.33% -4.28% 5.30% 5.66% -16.82%
Net Income Q/Q Growth
112.11% -404.07% -25.43% 26.56% -60.58% 114.67% -11.49% -4.34% -45.03% 93.73% -11.79%
EPS Q/Q Growth
111.99% -413.53% -23.56% 33.85% -64.19% 114.79% -10.58% -5.97% -45.08% 94.68% -11.74%
Operating Cash Flow Q/Q Growth
7.74% -36.71% 30.10% 49.00% -41.21% 7.54% 38.70% 35.42% -53.41% 76.80% -11.17%
Free Cash Flow Firm Q/Q Growth
61.74% 257.12% -21.63% 40.72% 38.75% -470.09% -8.79% 186.46% 33.20% -63.34% 69.07%
Invested Capital Q/Q Growth
-0.49% -6.53% -1.09% -0.39% 0.14% 7.02% -1.31% 1.34% 4.24% -4.28% -1.37%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
32.28% 28.35% 34.56% 34.47% 34.09% 35.92% 35.25% 37.64% 36.69% 36.27% 37.43%
EBITDA Margin
18.58% -8.81% 20.62% 22.95% 21.47% 31.69% 21.83% 22.64% 23.48% 32.45% 21.13%
Operating Margin
7.59% -16.73% 11.63% 14.78% 12.45% 13.12% 14.76% 15.56% 16.31% 14.89% 15.26%
EBIT Margin
6.35% -18.99% 11.88% 14.56% 13.03% 23.75% 14.15% 15.31% 15.99% 25.40% 13.58%
Profit (Net Income) Margin
2.63% -21.32% 6.96% 9.19% 7.36% 18.64% 8.57% 9.38% 10.10% 17.19% 9.87%
Tax Burden Percent
71.93% 98.60% 77.04% 78.78% 75.23% 90.54% 77.98% 77.29% 79.33% 77.21% 79.29%
Interest Burden Percent
57.60% 113.87% 76.04% 80.08% 75.12% 86.72% 77.71% 79.28% 79.60% 87.67% 91.62%
Effective Tax Rate
28.07% 0.00% 22.96% 21.22% 24.77% 9.47% 22.02% 22.71% 20.67% 22.79% 20.71%
Return on Invested Capital (ROIC)
3.95% -8.53% 6.55% 8.44% 6.88% 8.94% 8.97% 9.16% 10.07% 9.15% 8.66%
ROIC Less NNEP Spread (ROIC-NNEP)
2.62% -13.40% 5.52% 7.23% 5.94% 12.14% 7.71% 8.04% 8.82% 12.00% 7.85%
Return on Net Nonoperating Assets (RNNOA)
1.57% -7.39% 3.03% 4.27% 3.76% 7.79% 6.15% 6.67% 7.09% 9.37% 8.29%
Return on Equity (ROE)
5.52% -15.92% 9.57% 12.71% 10.64% 16.73% 15.11% 15.84% 17.17% 18.52% 16.96%
Cash Return on Invested Capital (CROIC)
6.27% 9.21% 2.40% 3.02% 1.50% -1.64% 9.53% 9.49% 4.28% 2.84% 5.11%
Operating Return on Assets (OROA)
3.24% -9.78% 6.18% 7.55% 6.76% 12.41% 7.96% 8.36% 8.86% 13.81% 7.11%
Return on Assets (ROA)
1.34% -10.98% 3.62% 4.77% 3.82% 9.75% 4.82% 5.12% 5.59% 9.35% 5.17%
Return on Common Equity (ROCE)
5.43% -15.68% 9.45% 12.53% 10.46% 16.45% 14.89% 15.59% 16.84% 18.17% 16.68%
Return on Equity Simple (ROE_SIMPLE)
-0.73% 0.00% 11.32% 11.97% 12.39% 0.00% 14.53% 15.07% 16.13% 0.00% 16.88%
Net Operating Profit after Tax (NOPAT)
54 -117 90 119 95 120 118 127 133 126 120
NOPAT Margin
5.46% -11.71% 8.96% 11.64% 9.37% 11.87% 11.51% 12.03% 12.94% 11.50% 12.10%
Net Nonoperating Expense Percent (NNEP)
1.34% 4.87% 1.02% 1.21% 0.94% -3.20% 1.26% 1.13% 1.25% -2.86% 0.81%
Return On Investment Capital (ROIC_SIMPLE)
0.94% -2.06% - - - 1.93% - - - 2.22% -
Cost of Revenue to Revenue
67.72% 71.65% 65.44% 65.53% 65.91% 64.08% 64.75% 62.36% 63.31% 63.73% 62.57%
SG&A Expenses to Revenue
18.07% 19.52% 19.73% 16.55% 18.42% 19.45% 17.15% 18.85% 16.99% 18.15% 18.57%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
24.70% 45.08% 22.94% 19.69% 21.64% 22.81% 20.49% 22.08% 20.38% 21.37% 22.17%
Earnings before Interest and Taxes (EBIT)
62 -190 120 149 132 241 145 162 165 279 134
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
183 -88 208 235 217 321 224 240 242 357 209
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
2.49 2.75 2.71 2.86 3.82 3.37 3.04 3.31 3.31 3.72 3.63
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
1.98 2.35 2.52 2.61 3.38 2.94 2.38 2.58 2.51 2.79 2.52
Price to Earnings (P/E)
0.00 428.75 24.16 24.10 31.27 25.55 21.16 22.23 20.73 22.80 21.86
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.23% 4.14% 4.15% 3.20% 3.91% 4.73% 4.50% 4.82% 4.39% 4.58%
Enterprise Value to Invested Capital (EV/IC)
1.90 2.14 2.13 2.20 2.77 2.47 2.25 2.37 2.33 2.56 2.28
Enterprise Value to Revenue (EV/Rev)
2.50 2.81 3.00 3.11 3.90 3.47 2.88 3.11 3.08 3.34 3.26
Enterprise Value to EBITDA (EV/EBITDA)
18.71 19.90 12.39 12.72 16.01 13.94 11.43 12.40 12.20 13.49 14.16
Enterprise Value to EBIT (EV/EBIT)
71.18 54.04 18.95 19.02 23.61 20.08 16.17 17.54 17.34 19.51 21.36
Enterprise Value to NOPAT (EV/NOPAT)
0.00 184.51 27.92 27.37 33.99 28.06 24.09 25.68 24.10 25.83 22.82
Enterprise Value to Operating Cash Flow (EV/OCF)
12.97 15.51 15.28 16.92 22.79 20.93 17.41 20.78 20.09 21.46 20.07
Enterprise Value to Free Cash Flow (EV/FCFF)
28.92 22.25 91.19 74.62 191.71 0.00 23.55 24.96 56.00 93.50 45.70
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.77 0.64 0.61 0.64 0.72 0.72 0.75 0.81 0.87 0.90 1.10
Long-Term Debt to Equity
0.77 0.64 0.61 0.64 0.72 0.72 0.75 0.81 0.87 0.90 1.10
Financial Leverage
0.60 0.55 0.55 0.59 0.63 0.64 0.80 0.83 0.80 0.78 1.06
Leverage Ratio
2.27 2.19 2.17 2.22 2.31 2.36 2.49 2.55 2.54 2.60 2.81
Compound Leverage Factor
1.31 2.50 1.65 1.78 1.74 2.05 1.93 2.02 2.02 2.28 2.58
Debt to Total Capital
43.65% 38.97% 37.80% 38.97% 41.80% 41.98% 42.87% 44.80% 46.50% 47.24% 52.38%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.04%
Long-Term Debt to Total Capital
43.65% 38.97% 37.80% 38.97% 41.80% 41.98% 42.87% 44.80% 46.50% 47.24% 52.34%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.82% 0.81% 0.74% 0.81% 1.00% 0.99% 0.76% 0.81% 0.82% 0.82% 0.80%
Common Equity to Total Capital
55.53% 60.22% 61.46% 60.21% 57.20% 57.04% 56.37% 54.39% 52.68% 51.93% 46.82%
Debt to EBITDA
4.66 3.91 2.37 2.41 2.65 2.58 2.37 2.56 2.66 2.75 3.38
Net Debt to EBITDA
3.84 3.19 1.91 2.00 2.08 2.07 1.93 2.08 2.18 2.19 3.15
Long-Term Debt to EBITDA
4.66 3.91 2.37 2.41 2.65 2.58 2.37 2.56 2.66 2.75 3.37
Debt to NOPAT
-18.40 36.28 5.34 5.20 5.63 5.19 4.98 5.30 5.25 5.26 5.44
Net Debt to NOPAT
-15.15 29.59 4.32 4.31 4.42 4.17 4.07 4.31 4.30 4.20 5.08
Long-Term Debt to NOPAT
-18.40 36.28 5.34 5.20 5.63 5.19 4.98 5.30 5.25 5.26 5.44
Altman Z-Score
2.07 2.28 2.47 2.55 2.87 2.61 2.42 2.42 2.31 2.42 2.09
Noncontrolling Interest Sharing Ratio
1.60% 1.52% 1.26% 1.39% 1.63% 1.64% 1.49% 1.56% 1.87% 1.86% 1.62%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
1.43 1.41 1.48 1.58 1.75 1.52 1.45 1.49 1.48 1.32 1.40
Quick Ratio
0.94 0.92 0.95 0.99 1.17 1.00 0.96 0.99 1.01 0.90 0.95
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
538 333 -212 -174 -294 -480 130 142 -164 -246 -151
Operating Cash Flow to CapEx
289.42% 210.75% 650.27% 490.14% 164.12% 282.09% 311.54% 219.82% 102.35% 263.70% 183.41%
Free Cash Flow to Firm to Interest Expense
19.31 11.79 -7.00 -5.32 -8.39 -14.30 3.84 4.06 -4.78 -7.07 -13.24
Operating Cash Flow to Interest Expense
6.16 5.64 8.31 5.91 3.71 6.59 6.09 4.23 3.18 6.75 11.67
Operating Cash Flow Less CapEx to Interest Expense
4.03 2.97 7.04 4.70 1.45 4.25 4.13 2.30 0.07 4.19 5.31
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.51 0.52 0.52 0.52 0.52 0.52 0.56 0.55 0.55 0.54 0.52
Accounts Receivable Turnover
5.21 5.40 5.23 5.22 5.22 5.39 5.37 5.40 5.51 5.70 5.28
Inventory Turnover
8.34 8.25 8.42 8.36 8.47 8.26 9.66 9.71 10.70 11.05 10.70
Fixed Asset Turnover
2.51 2.50 2.57 2.59 2.64 2.66 2.90 0.00 0.00 2.88 0.00
Accounts Payable Turnover
19.48 17.58 19.46 19.42 21.16 14.02 16.85 14.98 14.96 12.44 15.32
Days Sales Outstanding (DSO)
70.03 67.65 69.82 69.95 69.92 67.74 67.97 67.62 66.29 64.04 69.08
Days Inventory Outstanding (DIO)
43.74 44.23 43.34 43.63 43.10 44.19 37.78 37.58 34.11 33.03 34.12
Days Payable Outstanding (DPO)
18.74 20.76 18.76 18.80 17.25 26.04 21.67 24.37 24.40 29.34 23.83
Cash Conversion Cycle (CCC)
95.04 91.12 94.40 94.78 95.77 85.89 84.08 80.83 76.01 67.74 79.37
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
5,309 5,335 5,708 5,771 5,794 5,786 5,406 5,478 5,405 5,186 5,417
Invested Capital Turnover
0.72 0.73 0.73 0.73 0.73 0.75 0.78 0.76 0.78 0.80 0.72
Increase / (Decrease) in Invested Capital
-485 -450 302 294 389 600 -11 -15 298 373 270
Enterprise Value (EV)
10,070 11,393 12,165 12,690 16,052 14,315 12,148 12,987 12,587 13,296 12,328
Market Capitalization
7,955 9,520 10,239 10,641 13,899 12,127 10,048 10,761 10,290 11,086 9,537
Book Value per Share
$62.46 $67.69 $73.26 $72.27 $70.77 $70.12 $64.48 $63.53 $60.97 $58.50 $51.65
Tangible Book Value per Share
($6.55) ($2.12) ($2.34) ($3.05) ($5.01) ($7.06) ($9.07) ($11.62) ($14.73) ($16.29) ($21.96)
Total Capital
5,753 5,748 6,154 6,182 6,364 6,306 5,865 5,978 5,901 5,731 5,611
Total Debt
2,511 2,240 2,327 2,409 2,660 2,647 2,514 2,678 2,744 2,708 2,939
Total Long-Term Debt
2,511 2,240 2,327 2,409 2,660 2,647 2,514 2,678 2,744 2,708 2,937
Net Debt
2,067 1,827 1,880 1,998 2,090 2,127 2,055 2,178 2,248 2,162 2,745
Capital Expenditures (CapEx)
59 76 39 39 79 78 66 67 107 89 72
Debt-free, Cash-free Net Working Capital (DFCFNWC)
226 214 272 373 386 277 293 297 265 114 210
Debt-free Net Working Capital (DFNWC)
455 409 483 552 713 554 451 497 467 347 403
Net Working Capital (NWC)
455 409 483 552 713 554 451 497 467 347 401
Net Nonoperating Expense (NNE)
28 96 20 25 20 -69 30 28 29 -63 22
Net Nonoperating Obligations (NNO)
2,067 1,827 1,880 1,998 2,090 2,127 2,055 2,178 2,248 2,162 2,745
Total Depreciation and Amortization (D&A)
120 102 88 86 85 81 79 78 77 78 75
Debt-free, Cash-free Net Working Capital to Revenue
5.62% 5.29% 6.71% 9.14% 9.40% 6.70% 6.96% 7.10% 6.49% 2.86% 5.54%
Debt-free Net Working Capital to Revenue
11.32% 10.10% 11.88% 13.53% 17.35% 13.41% 10.69% 11.90% 11.41% 8.74% 10.66%
Net Working Capital to Revenue
11.32% 10.10% 11.88% 13.53% 17.35% 13.41% 10.69% 11.90% 11.41% 8.74% 10.61%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$0.50 ($4.20) $1.34 $1.75 $1.31 $3.66 $1.70 $1.89 $2.02 $3.68 $1.90
Adjusted Weighted Average Basic Shares Outstanding
50.68M 51.38M 51.39M 51.55M 51.44M 51.23M 51.28M 51.22M 51.10M 50.81M 50.87M
Adjusted Diluted Earnings per Share
$0.50 ($4.17) $1.33 $1.74 $1.30 $3.63 $1.69 $1.89 $2.01 $3.66 $1.88
Adjusted Weighted Average Diluted Shares Outstanding
50.85M 51.63M 51.58M 51.85M 51.84M 51.45M 51.61M 51.47M 51.43M 51.30M 51.28M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
49.12M 51.14M 51.14M 51.63M 51.51M 51.35M 51.30M 51.27M 51.18M 50.99M 50.88M
Normalized Net Operating Profit after Tax (NOPAT)
54 -117 90 119 95 120 118 127 133 126 120
Normalized NOPAT Margin
5.46% -11.71% 8.96% 11.64% 9.37% 11.87% 11.51% 12.03% 12.94% 11.50% 12.10%
Pre Tax Income Margin
3.66% -21.62% 9.04% 11.66% 9.79% 20.59% 10.99% 12.14% 12.73% 22.27% 12.45%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
2.24 -6.74 3.96 4.56 3.77 7.17 4.30 4.63 4.79 8.03 11.81
NOPAT to Interest Expense
1.93 -4.16 2.99 3.65 2.71 3.59 3.50 3.64 3.87 3.64 10.52
EBIT Less CapEx to Interest Expense
0.11 -9.42 2.68 3.35 1.50 4.84 2.35 2.71 1.68 5.47 5.45
NOPAT Less CapEx to Interest Expense
-0.20 -6.84 1.71 2.44 0.45 1.25 1.55 1.72 0.77 1.08 4.16
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
-1,985.83% 471.22% 27.85% 4.14% 3.21% 5.03% 5.03% 4.93% 4.72% 7.85% 8.74%

Frequently Asked Questions About Charles River Laboratories International's Financials

When does Charles River Laboratories International's financial year end?

According to the most recent income statement we have on file, Charles River Laboratories International's fiscal year ends in December. Their fiscal year 2024 ended on December 28, 2024.

How has Charles River Laboratories International's net income changed over the last 9 years?

Charles River Laboratories International's net income appears to be on an upward trend, with a most recent value of $25.29 million in 2024, falling from $151.09 million in 2015. The previous period was $480.37 million in 2023. Check out Charles River Laboratories International's forecast to explore projected trends and price targets.

What is Charles River Laboratories International's operating income?
Charles River Laboratories International's total operating income in 2024 was $227.35 million, based on the following breakdown:
  • Total Gross Profit: $1.33 billion
  • Total Operating Expenses: $1.10 billion
How has Charles River Laboratories International revenue changed over the last 9 years?

Over the last 9 years, Charles River Laboratories International's total revenue changed from $1.36 billion in 2015 to $4.05 billion in 2024, a change of 197.1%.

How much debt does Charles River Laboratories International have?

Charles River Laboratories International's total liabilities were at $4.02 billion at the end of 2024, a 11.4% decrease from 2023, and a 208.6% increase since 2015.

How much cash does Charles River Laboratories International have?

In the past 9 years, Charles River Laboratories International's cash and equivalents has ranged from $117.63 million in 2016 to $276.77 million in 2023, and is currently $194.61 million as of their latest financial filing in 2024.

How has Charles River Laboratories International's book value per share changed over the last 9 years?

Over the last 9 years, Charles River Laboratories International's book value per share changed from 15.72 in 2015 to 67.69 in 2024, a change of 330.5%.



This page (NYSE:CRL) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners